Rising metabolic score for insulin resistance (METS-IR) levels strongly correlate with major cardiovascular events (MACE) and ...

In advanced non–small cell lung cancer (NSCLC), discontinuing immunotherapy after 2 years can maintain durable responses ...

Making treatment for non–small cell lung cancer (NSCLC) accessible to a wide range of the population can help to improve ...

The humanized IgG4 monoclonal antibody was first approved for myasthenia gravis in the US in 2023, with approvals in Japan ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Patients with alopecia universalis and alopecia totalis are at a particularly high risk of cardiovascular disease, a new ...

US adults who were displaced and never returned home due to a natural disaster had the highest odds of developing depression or anxiety.

A new study finds that drugmakers’ use of overlapping patents delayed generic entry for 4 top-selling drugs, driving billions in excess spending.

Panelists discuss the challenges of biologic access in hidradenitis suppurativa due to utilization management policies like step therapy, emphasizing the need for patient education, strategic planning ...

Panelists discuss the anticipated 2026 updates to the American Academy of Dermatology guidelines for hidradenitis suppurativa, highlighting efforts to unify treatment protocols, support biologic ...

James Chalmers, MBChB, PhD, highlights the reassuring safety and tolerability profile of brensocatib in patients with non–cystic fibrosis bronchiectasis.

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.